A Disintegrin And Metalloproteinase
From Proteopedia
(Difference between revisions)
| Line 15: | Line 15: | ||
== Disease == | == Disease == | ||
| - | ADAM inhibitors are used in anti-cancer therapy. ADAM10 is a therapeutic target for cancer and inflammation <ref>PMID:19601831</ref>. ADAM17 is a therapeutic target for multiple diseases <ref>PMID:19601834</ref>.ADAM33 is implicated in asthma. ADAMTS13 cleaves von Willebrand factor involved in blood clotting. ADAM33 is a therapeutic target for asthma <ref>PMID: | + | ADAM inhibitors are used in anti-cancer therapy. ADAM10 is a therapeutic target for cancer and inflammation <ref>PMID:19601831</ref>. ADAM17 is a therapeutic target for multiple diseases <ref>PMID:19601834</ref>.ADAM33 is implicated in asthma. ADAMTS13 cleaves von Willebrand factor involved in blood clotting. ADAM33 is a therapeutic target for asthma <ref>PMID:38396994</ref>. |
== 3D Structures of A Disintegrin And Metalloproteinase == | == 3D Structures of A Disintegrin And Metalloproteinase == | ||
Revision as of 10:22, 19 May 2024
| |||||||||||
References
- ↑ Edwards DR, Handsley MM, Pennington CJ. The ADAM metalloproteinases. Mol Aspects Med. 2008 Oct;29(5):258-89. doi: 10.1016/j.mam.2008.08.001. Epub 2008, Aug 15. PMID:18762209 doi:http://dx.doi.org/10.1016/j.mam.2008.08.001
- ↑ Crawford HC, Dempsey PJ, Brown G, Adam L, Moss ML. ADAM10 as a therapeutic target for cancer and inflammation. Curr Pharm Des. 2009;15(20):2288-99. PMID:19601831 doi:10.2174/138161209788682442
- ↑ Arribas J, Esselens C. ADAM17 as a therapeutic target in multiple diseases. Curr Pharm Des. 2009;15(20):2319-35. PMID:19601834 doi:10.2174/138161209788682398
- ↑ Sleziak J, Gawor A, Błażejewska M, Antosz K, Gomułka K. ADAM33's Role in Asthma Pathogenesis: An Overview. Int J Mol Sci. 2024 Feb 15;25(4):2318. PMID:38396994 doi:10.3390/ijms25042318
